Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise Vrancken

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|July 28, 2025
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumorsMégane Jassin, Alix Block, Laury Désiront, et al.
Frontiers in Immunology|December 18, 2025
Correction: From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumorsMégane Jassin, Alix Block, Laury Désiront, et al.
Revue Medicale Suisse|August 24, 2018
[What is new in the management of multiple myeloma]Louise Vrancken, Joséphine Muller, Margaux Lejeune, et al.
Journal of Hematology & Oncology|June 7, 2022
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?David Kegyes, Catalin Constantinescu, Louise Vrancken, et al.
Blood Cancer Journal|November 10, 2018
Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblastsSylvia Faict, Joséphine Muller, Kim De Veirman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2018
In Vitro Th17-Polarized Human CD4<sup>+</sup> T Cells Exacerbate Xenogeneic Graft-versus-Host DiseaseLoïc Delens, Grégory Ehx, Joan Somja, et al.
Frontiers in Immunology|July 22, 2022
Radiotheranostic Agents in Hematological MalignanciesJo Caers, Elodie Duray, Louise Vrancken, et al.
British Journal of Haematology|April 2, 2020
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour geneArnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|July 28, 2025
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumorsMégane Jassin, Alix Block, Laury Désiront, et al.
Frontiers in Immunology|December 18, 2025
Correction: From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumorsMégane Jassin, Alix Block, Laury Désiront, et al.
Revue Medicale Suisse|August 24, 2018
[What is new in the management of multiple myeloma]Louise Vrancken, Joséphine Muller, Margaux Lejeune, et al.
Journal of Hematology & Oncology|June 7, 2022
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?David Kegyes, Catalin Constantinescu, Louise Vrancken, et al.
Blood Cancer Journal|November 10, 2018
Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblastsSylvia Faict, Joséphine Muller, Kim De Veirman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2018
In Vitro Th17-Polarized Human CD4<sup>+</sup> T Cells Exacerbate Xenogeneic Graft-versus-Host DiseaseLoïc Delens, Grégory Ehx, Joan Somja, et al.
Frontiers in Immunology|July 22, 2022
Radiotheranostic Agents in Hematological MalignanciesJo Caers, Elodie Duray, Louise Vrancken, et al.
British Journal of Haematology|April 2, 2020
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour geneArnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, et al.
Pageof 1